SAN DIEGO and SUZHOU, China, March 13, 2025 — Adagene Inc. (Nasdaq: ADAG), a company focused on revolutionizing the creation and advancement of innovative antibody-based therapies, announced today that it will be presenting at the 11th Annual Immuno-Oncology 360⁰ Summit in Boston on March 26, 2025.
The summit is tailored for pharma/biotech companies of all sizes, academic institutions, and investors who are looking to harness the power of a patient’s immune system to fight cancer. It offers a platform to learn directly from scientific and business experts about the latest data impacting the immuno-oncology field.
Immuno-Oncology 360⁰ Summit
- Title: ADG126 SAFEbody®: Targeting CTLA-4+ Tregs to Overcome MSS CRC Resistance
- Date: Wednesday, March 26, 2025
- Time: 11:30 AM – 11:50 AM Eastern Time
- Onsite Location: Sheraton Boston Hotel, Track 2, Back Bay Ballroom AB
Following the presentation, the presentation slides will be accessible on the Presentations section of the Company’s website.
About Adagene
Adagene Inc. (Nasdaq: ADAG) is a clinical-stage, platform-driven biotechnology company dedicated to transforming the discovery and development of innovative antibody-based cancer immunotherapies. Adagene utilizes computational biology and artificial intelligence to engineer novel antibodies that address unmet global patient needs. The company has established strategic collaborations with well-known global partners, leveraging its SAFEbody® precision masking technology in various cutting-edge scientific approaches.
Driven by its proprietary Dynamic Precision Library (DPL) platform, which includes NEObody™, SAFEbody, and POWERbody™ technologies, Adagene’s highly differentiated pipeline showcases novel immunotherapy programs. The company’s SAFEbody technology is designed to improve the safety and tolerability of antibody therapeutics by employing precision masking to shield the binding domain of the biologic therapy. Activation within the tumor microenvironment enables tumor-specific targeting of antibodies, minimizing off-target toxicity in healthy tissues.
Adagene’s leading clinical program, ADG126 (muzastotug), is a masked, anti-CTLA-4 SAFEbody that targets a specific epitope of CTLA-4 in regulatory T cells (Tregs) within the tumor microenvironment. ADG126 is currently undergoing phase 1b/2 clinical studies in combination with anti-PD-1 therapy, with a focus on Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC). Supported by ongoing clinical research, the SAFEbody platform can be applied to various antibody-based therapeutic modalities, including Fc empowered antibodies, antibody-drug conjugates, and bi/multispecific T-cell engagers.
For more information, please visit: .
Follow Adagene on , and .
SAFEbody® is a registered trademark in the United States, China, Australia, Japan, Singapore, and the European Union.
Safe Harbor Statement
This press release contains forward-looking statements, including statements regarding certain clinical results of ADG126, the potential implications of clinical data for patients, and Adagene’s advancement of, and anticipated preclinical activities, clinical development, regulatory milestones, and commercialization of its product candidates. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including but not limited to Adagene’s ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may not support further development or regulatory approval; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of Adagene’s drug candidates; Adagene’s ability to achieve commercial success for its drug candidates, if approved; Adagene’s ability to obtain and maintain protection of intellectual property for its technology and drugs; Adagene’s reliance on third parties to conduct drug development, manufacturing and other services; Adagene’s limited operating history and Adagene’s ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates; Adagene’s ability to enter into additional collaboration agreements beyond its existing strategic partnerships or collaborations, and the impact of the COVID-19 pandemic on Adagene’s clinical development, commercial and other operations, as well as those risks more fully discussed in the “Risk Factors” section in Adagene’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Adagene, and Adagene undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.
Investor Contacts:
Raymond Tam
Raymond_tam@adagene.com
Bruce Mackle
LifeSci Advisors
